What do systematic reviews say?

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.87 [0.83, 0.92]
  27 studies · 39180 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.98 [0.84, 1.15]
  2 studies · 2563 participants
  High

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.07 [0.64, 1.78]
  1 study · 968 participants
  Moderate

Intervention not reported

• Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma 2015 · Cochrane Headline outcomes only
  no estimate extracted
  185 participants
  Low

Intervention not reported

The intervention leads to lower overall survival (OS) (high certainty).

• Trastuzumab containing regimens for early breast cancer 2012 · Cochrane Headline outcomes only
  HR 0.66 [0.57, 0.77]
  8 studies · 9945 participants
  High

High‐dose chemotherapy vs chemotherapy without bone marrow transplant or stem cell rescue

High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).

• High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for… 2016 · Cochrane Headline outcomes only
  RR 1 [0.96, 1.04]
  8 studies · 3566 participants
  High

OFS vs no OFS

OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.86 [0.78, 0.94]
  11 studies · 10374 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.91 [0.83, 0.99]
  9 studies · 13949 participants
  High

Hepatic resection vs radiofrequency ablation

• Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 578 participants
  Moderate

Percutaneous ethanol injection vs radiofrequency ablation

• Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma 2013 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1088 participants
  Moderate

Laparoscopy vs laparotomy

Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer 2018 · Cochrane Headline outcomes only
  HR 1.04 [0.86, 1.25]
  6 studies · 3993 participants
  Moderate

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.89 [0.81, 0.98]
  8 studies · 13547 participants
  Moderate

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  HR 0.76 [0.6, 0.97]
  1 study · 552 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.99 [0.88, 1.12]
  8 studies · 13175 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

• Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1008 participants
  High

Intervention not reported

• Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  925 participants
  High